Investors Research Corp Salarius Pharmaceuticals, Inc. Transaction History

Investors Research Corp

  • $446 Million
  • Q3 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2021

Jan 27, 2022
SELL
$0.49 - $1.01 $12 - $25
-25 Closed
0 $0
Q3 2021

Oct 27, 2021
BUY
$0.8 - $1.15 $11 - $16
14 Added 127.27%
25 $0
Q1 2021

Apr 28, 2021
BUY
$1.0 - $3.0 $11 - $33
11 New
11 $0

About Salarius Pharmaceuticals, Inc.

SLRX Quotes by TradingView
  • Ticker SLRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 2,244,650
  • Market Cap $3.37M
  • Description
  • Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a ...
More about SLRX
Track This Portfolio

Track Investors Research Corp Portfolio

Follow Investors Research Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Investors Research Corp, based on Form 13F filings with the SEC.

News

Stay updated on Investors Research Corp with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email